Abstract
Utilising daily-updated data, plus an extensive new review of R&D investment, this essential report examines the research investment and drug pipelines for 39 leading companies.
Few issues occupy as much executive and analyst time as the productivity of the industry' s research and development effort. Many forecast the impending doom of the ethical industry as we know it, citing the imbalance of patent expiries against new product launches, the absence of any real recent blockbusters and the rise of generic competition and regulatory demands.
Fundamental questions need answers
- But what is the real situation in pharma R&D?
- What is the new product launch calendar looking like?
- What are the latest clinical trial results?
- What is the status, by development phase, of companies' R&D pipelines?
- Which companies are committing most investment to their R&D effort?
This report provides key information
Executives need current and independent information to answer these and similar questions. That is why Espicom Business Intelligence - the leading provider of pharmaceutical competitive intelligence - has published The Pharma R&D Fact Book 2007.
This essential report examines the research investment and drug pipelines for 39 leading companies from Abbott and Alcon to UCB and Wyeth. A complete list of companies in the report is provided below.
Utilising daily-updated data, plus an extensive review of R&D investment, the 600+ page report contains a wealth of essential information including:
- At-a-glance bullet point summaries of key business facts and events for each company.
- Extensive analysis of R&D investment, dating back to 1997 with forecasts to 2011.
- Analysis of investment by US, European and Japanese companies .
- Research ratios by company, region and 10-year change. Company-by-company graphs showing their performance against the industry average.
- R&D pipeline and graphs for each company showing the numbers of compounds in development by stage, split by novel compounds, new indications and new formulations.
- Extensive monographs of each company' s pipeline showing key data such as development status, clinical trial results, licensing and deals.
Table of Contents
Volume 1
Introduction
- The Cost of Developing a New Drug
- The Drug Development Process
- Regulatory Changes
- ..the situation in the US
- Post-regulation .. the Role of Watchdogs
- Generics
- The Way Forward
- Notes & Definitions
- Company Notes
DATA TABLES
- Exchange Rates (against US$)
- Country and Region of Domicile, Reporting Year-End, Currency and Revenues from Pharmaceutical Products
- Total Revenues by Company 1997-2011 (Local Currency)
- R&D Expenditure by Company 1997-2011 (Local Currency)
- Five Year Change in R&D Expenditure Ranked by Value 2002-2006
- (US$ million, at Constant 2002 Exchange Rates; Mean Change=72.5; SD=73.87)
- Five Year Change in R&D Expenditure Ranked by Percentage Change 2002-2006
- (US$ million, at Constant 2002 Exchange Rates; Mean Change=72.5; SD=73.87)
- Ten Year Change in R&D Expenditure 1997-2006
- (US$ million, at Constant 1997 Exchange Rates; Mean Change=205.6; SD=226.9)
- Predicted Change in R&D Expenditure Ranked by Value 2006-2011
- (US$ million, at Constant 2006 Exchange Rates)
- Predicted Change in R&D Expenditure Ranked by Percentage Change 2006-2011
- (US$ million, at Constant 2006 Exchange Rates)
- US Companies by R&D Expenditure by Company 2002-2006 (US$ million)
- R&D Expenditure for Top Ten US Companies
- European Companies by R&D Expenditure 2002-2006 (US$ million)
- R&D Expenditure for Top Ten European Companies
- Japanese Companies by R&D Expenditure 2002-2006 (US$ million)
- R&D Expenditure for Top Ten Japanese Companies
- Total R&D Expenditure for Featured Companies
- Research Ratio (%) by Company 1997-2011
- Five Year Change in R&D Ratio (%) Ranked by Value 2002-2006 (Mean Change=2.5; SD=5.84)
- Five Year Change in R&D Ratio (%) Ranked by Point Change 2002-2006 (Mean Change=2.5; SD=5.84)
- Ten Year Change in R&D Ratio (%) by Point Change 1997-2006 (Mean Change=1.4; SD=5.87)
- Predicted Change in R&D Ratio (%) by Value 2006-2011 (Mean Change=0.0)
- Predicted Change in R&D Ratio (%) by Point Change 2006-2011 (Mean Change=0.90)
- US Companies by Five Year Change in R&D Ratio (%) by Point Change 2002-2006 (Mean Change=2.2 SD=7.92)
- Research Ratios for Top Ten US Companies
- European Companies by Five Year Change in R&D Ratio (%) by Point Change 2002- 2006 (Mean Change=0.9; SD=2.49)
- Research Ratios for Top European Companies
- Japanese Companies by Five Year Change in R&D Ratio (%) by Point Change 2002-2006 (Mean Change=4.8; SD=2.54)
- Research Ratios for Top Ten Japanese Companies
- R&D Pipeline Summary Table 2007 - Products by Trial Phase
Abbott
- R&D PIPELINE
- INFLAMMATION
- ANTI-INFECTIVES
- NEUROSCIENCE
- VIROLOGY
- CARDIOVASCULAR
- ONCOLOGY
- GASTROINTESTINAL
- OTHERS
Alcon
- R&D PIPELINE
- OPHTHALMOLOGY
- OTIC
Allergan
- R&D PIPELINE
- NEUROSCIENCES
- OPTHTHALMOLOGY
- MEDICAL DERMATOLOGY
- OTHER
Amgen
- R&D PIPELINE
- HAEMATOLOGY
- IMMUNOLOGY
- INFLAMMATION
- ONCOLOGY
- OTHER
Astellas Pharma
- R&D PIPELINE
- CARDIOVASCULAR
- UROLOGY
- INFLAMMATION & IMMUNOLOGY
- GASTROINTESTINAL
- INFECTIOUS DISEASE
- CENTRAL NERVOUS SYSTEM
- METABOLIC
- BONE DISORDERS
- ONCOLOGY
AstraZeneca
- R&D PIPELINE
- GASTROINTESTINAL
- CARDIOVASCULAR
- NEUROSCIENCE
- CANCER
- RESPIRATORY AND INFLAMMATION
- INFECTION
Bayer
- R&D PIPELINE
- WOMEN' S HEALTHCARE
- HEMATOLOGY/CARDIOLOGY
- DIAGNOSTIC IMAGING
- SPECIALIZED THERAPEUTICS
- ONCOLOGY
Boehringer Ingelheim
- R&D PIPELINE
- RESPIRATORY
- CARDIOVASCULAR
- UROLOGY
- CENTRAL NERVOUS SYSTEM
- IMMUNOLOGY AND INFLAMMATION
- VIROLOGY
- ONCOLOGY
- METABOLIC
Bristol-Myers Squib
- R&D PIPELINE
- CARDIOVASCULAR AND METABOLIC DISEASES
- VIROLOGY
- NEUROSCIENCE
- ONCOLOGY
- IMMUNOLOGY
- OTHERS
Chugai Pharmaceutical
- R&D PIPLINE
- ONCOLOGY
- RENAL DISEASES
- TRANSPLANT, IMMUNOLOGY AND INFECTIOUS DISEASES
- BONE AND JOINT
- CARDIO/CEREBRO-VASCULAR
- OTHER
Daichi Sankyo
- R&D PIPELINE
- CARDIOVASCULAR
- METABOLISM
- INFECTION
- IMMUNITY AND ALLERGY
- BONE AND JOINTS
- CANCER
- OTHERS
Dainipon Sumitomo Pharma
- R&D PIPELINE
- CARDIOVASCULAR
- ONCOLOGY/INFECTION
- INFLAMMATION/ALLERGY
- CENTRAL NERVOUS SYSTEM
- DIABETES
- OTHER
Eisai
- R&D PIPELINE
- NEUROLOGY
- GASTROENTEROLOGY
- CARDIOVASCULAR AND RESPIRATORY
- METABOLIC
- DIAGNOSTICS
- ANTI-INFECTIVES
- ONCOLOGY
- OTHER
EliLily
- R&D PIPELINE
- NEUROSCIENCE
- ENDOCRINE DISEASES
- ONCOLOGY
- CARDIOVASCULAR
- ANTI-INFECTIVES
- OTHERS
Forest Laboratories
- R&D PIPELINE
- CENTRAL NERVOUS SYSTEM
- CARDIOVASCULAR
- OTHER
Gilead
- R&D PIPELINE
- ANTI-VIRAL
- OTHERS
GlaxoSmithKline
- R&D PIPELINE
- RESPIRATORY
- NEUROSCIENCES
- ANTIVIRALS
- ANTIBACTERIALS/ANTIMALARIALS
- METABOLIC
- VACCINES
- CARDIOVASCULAR
- UROGENITAL
- ONCOLOGY AND EMESIS
- GASTROINTESTINAL
- MUSCULOSKELETAL & INFLAMMATION
Volume 2
JOHNSON & JOHNSON
- R&D PIPELINE
- CENTRAL NERVOUS SYSTEM
- HAEMATOLOGY
- IMMUNOLOGY
- ANTI-INFECTIVE
- GASTROINTESTINAL
- REPRODUCTIVE HEALTH
- ONCOLOGY
- CARDIOVASCULAR
- OTHER
KYOWA HAKKO
- R&D PIPELINE
- ANTI-ALLERGY
- CENTRAL NERVOUS SYSTEM
- ANTICANCER
- GASTROINTESTINAL
- OTHERS
LUNDBECK
- R&D PIPELINE
- CENTRAL NERVOUS SYSTEM
MERCK KGAA
- R&D PIPELINE
- NEUROLOGY
- CARDIOMETABOLIC CARE
- METABOLISM
- REPRODUCTIVE HEALTH
- ONCOLOGY
- AUTOIMMUNE / INFLAMMATORY
- OTHER
MERCK & CO
- R&D PIPELINE
- CARDIOVASCULAR
- RESPIRATORY
- ANTI-INFLAMMATORY
- VACCINES & BIOLOGICALS
- ANTIBACTERIALS/ANTIFUNGALS
- OPHTHALMOLOGICAL
- UROLOGY
- NEUROLOGY
- METABOLIC
- ONCOLOGY
- HIV
- OTHERS
MITSUBISHI PHARMA
- R&D PIPELINE
- CIRCULATORY SYSTEM AND METABOLISM
- NEUROPSYCHIATRY
- RESPIRATORY SYSTEM AND IMMUNOLOGY
- ONCOLOGY AND HEPATOLOGY
- OTHER
NOVARTIS
- R&D PIPELINE
- CARDIOVASCULAR AND METABOLISM
- ONCOLOGY/HAEMATOLOGY
- NEUROSCIENCE
- ARTHRITIS/BONE
- GASTROINTESTINAL
- RESPIRATORY/DERMATOLOGY
- TRANSPLANTATION/IMMUNOLOGY
- INFECTIOUS DISEASES
- OPHTHALMICS
NOVO NORDISK
- R&D PIPELINE
- DIABETES CARE
- BIOPHARMACEUTICALS
NYCOMED
- R&D PIPELINE
- PAIN
- RESPIRATORY
- OTHERS
OTSUKA
- R&D PIPELINE
- CARDIOVASCULAR
- GASTROINTESTINAL
- CENTRAL NERVOUS SYSTEM
- ANTICANCER
- ANTI-INFECTIVE
- RESPIRATORY
- OTHERS
PFIZER
- R&D PIPELINE
- CARDIOVASCULAR / METABOLISM
- CENTRAL NERVOUS SYSTEM
- INFECTIOUS AND RESPIRATORY
- UROLOGY
- ARTHRITIS AND PAIN
- ONCOLOGY
- OPHTHALMOLOGY
- ENDOCRINE DISORDERS
- WOMEN' S HEALTHCARE
- OTHER
PROCTER & GAMBLE
- R&D PIPELINE
- MUSCUOLOSKELETAL
- GASTROINTESTINAL
- CARDIOVASCULAR
RECORDATI
- R&D PIPELINE
- CARDIOVASCULAR
- CENTRAL NERVOUS SYSTEM
- GASTROENTEROLOGY/UROLOGY
- RESPIRATORY
- ANTI-INFECTIVES
- OTHERS
ROCHE
- R&D PIPELINE
- ONCOLOGY
- VIROLOGY/INFECTIOUS DISEASES
- INFLAMMATORY, AUTOIMMUNE AND TRANSPLANTATION
- METABOLISM & BONE
- ANAEMIA
- CARDIOVASCULAR
- CENTRAL NERVOUS SYSTEM
- RESPIRATORY
- OPHTHALMOLOGY
- OTHERS
SANOFI-AVENTIS
- R&D PIPELINE
- CARDIOVASCULAR / THROMBOSIS
- ONCOLOGY
- CENTRAL NERVOUS SYSTEM
- METABOLISM / DIABETES
- VACCINES
- RESPIRATORY / ALLERGY
- ARTHRITIS / OSTEOPOROSIS
- GENITO-URINARY
- ANTI-INFECTIVE
- OTHER
SCHERING-PLOUGH
- R&D PIPELINE
- ALLERGY & RESPIRATORY
- ANTIVIRAL
- ANTI-INFLAMMATORY
- ONCOLOGY
- ANTI-INFECTIVES
- CARDIOVASCULAR
- OTHERS
SHIONOGI
- R&D PIPELINE
- INFECTIOUS DISEASES
- METABOLIC SYNDROME
- ANTICANCER
- NEUROLOGY
- ALLERGY
- CIRCULATORY SYSTEM
- OTHER
SOLVAY
- R&D PIPELINE
- CARDIOMETABOLICS
- WOMEN' S AND MEN' S HEALTH
- NEUROSCIENCE
- PANCREATIC ENZYMES
- INFLUENZA VACCINES
- OTHERS
TAKEDA
- R&D PIPELINE
- METABOLIC
- CARDIOVASCULAR
- GASTROINTESTINAL
- ANTICANCER
- MUSCULOSKELETAL
- CENTRAL NERVOUS SYSTEM
- OTHERS
TANABE
- R&D PIPELINE
- CARDIOVASCULAR AND RESPIRATORY SYSTEM
- CENTRAL AND PERIPHERAL NERVOUS SYSTEM
- IMMUNOLOGY AND INFLAMMATION
- OTHERS
UCB
- R&D PIPELINE
- CENTRAL NERVOUS SYSTEM
- IMMUNO-ALLERGOLOGY
- ONCOLOGY
- OTHERS
WYETH
- R&D PIPELINE
- NEUROSCIENCE
- GASTROENTEROLOGY
- VACCINES
- MUSCULOSKELETAL
- WOMEN' S HEALTHCARE / CONTRACEPTION
- ANTI-INFECTIVES
- IMMUNOLOGY
- ONCOLOGY
- CARDIOVASCULAR & METABOLIC DISORDERS
- OTHERS
